Table 1 Demographic and clinical characteristics at baseline and 1-year follow-up
| Â | Typically developing control subjects | 22q11.2 deletion carriers | 22q11.2 duplication carriers |
|---|---|---|---|
Baseline | |||
 ntotal | 88 | 107 | 42 |
 nSIPS | 74 | 85 | 34 |
 Age, years (SD) | 14.65 (7.4) | 14.56 (8.0) | 16.26 (13.1) |
 Age range, years | 6–45 | 6–43 | 5–49 |
 Males, n (%) | 41 (47.1%) | 53 (50.0%) | 23 (54.8%) |
 Non-white, n (%)a,b | 27 (30.7%) | 10 (9.3%) | 1 (2.4%) |
 Highest parental education, years (SD)c | 16.78 (3.3) | 17.17 (2.5) | 15.41 (2.7) |
 Poor sleepers, n (%)d,e | 3 (3.4%) | 34 (31.8%) | 14 (33.3%) |
 Psychosis, n (%)c,d | 0 (0%) | 12 (11.2%) | 0 (0%) |
 ASD, n (%)d,e | 0 (0%) | 48 (44.9%) | 17 (40.5%) |
 Medication, n (%)d,e | |||
  Anti-psychotics | 0 | 13 (12.1%) | 4 (9.5%) |
  Mood stabilizers | 2 (2.3%) | 12 (11.4%) | 3(7.1%) |
  Stimulants | 2 (2.3%) | 3 (2.9%) | 6 (14.3%) |
  Other medication | 1 (1.1%) | 8 (7.6%) | 2 (4.8%) |
  No medication | 83 (94.3%) | 69 (65.7%) | 27 (64.3%) |
One-year follow-up | |||
 ntotal | 42 | 62 | 20 |
 nSIPS | 32 | 52 | 17 |
 Age, years (SD) | 14.12 (5.9) | 16.18 (7.2) | 14.55 (9.1) |
 Age range, years | 7–30 | 7–41 | 6–44 |
 Males, n (%) | 18 (43.9%) | 27 (43.5%) | 13 (65.0%) |
 Non-white, n (%) | 8 (19.0%) | 9 (14.5%) | 1 (5.0%) |
 Highest parental education, years (SD) | 17.86 (2.9) | 17.00 (2.2) | 15.42 (3.1) |
 Poor sleepers, n (%)d,e | 1 (2.4%) | 19 (30.6%) | 7 (35.0%) |
 Psychosis, n (%) | 0 (0%) | 6 (9.8%) | 0 (0%) |
 ASD, n (%)d,e | 0 (0%) | 22 (36.1%) | 9 (45.0%) |
 Medication, n (%)d,e |  |  |  |
  Anti-psychotic | 1 (2.4%) | 8 (13.1%) | 0 (0%) |
  Mood stabilizer | 1 (3.2%) | 7 (11.5%) | 6 (30.0%) |
  Stimulants | 2 (4.9%) | 3 (4.9%) | 1 (5.0%) |
  Other medication | 0 (0%) | 4 (6.6%) | 1 (5.0%) |
  No medication | 37 (90.2%) | 39 (63.9%) | 12 (60.0%) |